W. Jean  Dodds

Dr. W. Jean Dodds

HEMOPET
+1
orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2020
Verified
Journal Article
Closed access
W. Jean  DoddsW. Jean Dodds
W. Jean Dodds
LLLaurie J. Larson
Laurie J. Larson
KCKris L. Christine
Kris L. Christine
RSRonald D. Schultz
Ronald D. Schultz

2 June 2020 in Veterinary Medicine and Science
Verified
Journal Article
Open access
PDF file
VPValerie Palmieri
Valerie Palmieri
W. Jean  DoddsW. Jean Dodds
W. Jean Dodds
JMJudy Morgan
Judy Morgan
ECElizabeth Carney
Elizabeth Carney
HFHerbert A. Fritsche
Herbert A. Fritsche
JKJon P. Kimball
Jon P. Kimball
A veterinarian and pet owner survey (Project Jake) examined the use and safety of isoxazoline parasiticides given to dogs. Data were received during August 1–31, 2018 from a total of 2,751 survey responses. Forty‐two percent (1,157) reported no flea treatment or adverse events (AE), while 58% (1594) had been treated with some parasiticide for flea control, and of those that received a parasiticide, the majority, or 83% (1,325), received an isooxazoline. When any flea treatment was given, AE were reported for 66.6% of respondents, with no apparent AE noted for 36.1%. Project Jake findings were compared to a retrospective analysis of publicly available Food and Drug Administration (FDA) and European Medicines Agency (EMA) reported AE. The number of total AE reported to FDA and EMA were comparable, although a 7 to 10 times higher occurrence of death and seizures was reported from the EMA or from outside the United States (US). Serious AE responses for death, seizures and neurological effects reported in our survey were higher than the FDA but moderately lower than the EMA reports. These sizable global data sets combined with this pre‐ and post‐parasiticide administration survey indicated that isoxazoline neurotoxicity was not flea‐ and tick‐specific. Post‐marketing serious AE were much higher than in Investigational New Drug (IND) submissions. Although the labels have recently been updated, dogs, cats and their caregivers remain impacted by their use. These aggregate data reports support the need for continued cross‐species studies and critical review of product labelling by regulatory agencies and manufacturers.

6 August 2019 in Animals
Verified
Journal Article
Open access
PDF file
W. Jean  DoddsW. Jean Dodds
W. Jean Dodds
This prospective study assessed the efficacy of a novel saliva-based immunoassay of IgA- and IgM-antibodies in predicting feline food sensitivities and intolerances. Clinical samples were obtained from 1000 cats proven or suspected to have food intolerances. Most were of domestic shorthair breed type, over 10 years of age, and weighed around 5 kg; they were equally distributed between spayed females and neutered males. Saliva was collected after at least an 8-h fast with a dental cotton rope, placed in a double-sleeved saliva collection tube, and sent to the laboratory. Salivary antibodies elicited by 24 common foods were measured with goat anti-canine IgA and IgM. Low reacting foods were lamb, cow milk, pork, turkey, wheat (lowest) and white-colored fish, whereas high reacting foods were millet, white potato, rice (highest) and salmon. Thus, the novel salivary-based food sensitivity and intolerance test, described previously for canines, also provided a reliable and clinically predictive alternative to food elimination trials, serum-based food allergy testing, and skin patch testing in cats. Manufacturers of commercial cat foods and treats, as well as those making homemade diets and treats for cats, should consider avoiding the more highly reactive foods as determined by the present study.

27 January 2021 in Vaccines
Verified
Journal Article
Open access
PDF file
W. Jean  DoddsW. Jean Dodds
W. Jean Dodds
Development of the immune system of mammalian animal species parallels that of humans and involves the innate and adaptive (acquired) immune responses acting together with the thymus gland. Consequently, issues surrounding the adequacy and safety of vaccinations to protect pet animals from their relevant infectious diseases need to be addressed just as they are for humans. Pet animals, especially canines, also have unique needs because of the wide diversity of purebred and mixed breeds that vary greatly in size, type, temperament, and even maturation rates. Furthermore, pets in early life encounter a series of changes that can affect their development and induce stressors including parasite control, new homes and environment, novel foods, and the socialization that is essential at a time when vaccinations need to be given. While recognizing that this overall need is becoming more understood, current vaccination policy guidelines for companion animals are still only adhered to by about 40% of veterinarians worldwide. Clearly, vaccination of pets should no longer be considered as “one size fits all”.

26 December 2022 in Animals
Verified
Journal Article
Open access
PDF file
W. Jean  DoddsW. Jean Dodds
W. Jean Dodds
Animal models of human and animal diseases have long been used as the lynchpin of experimental and clinical research. With the discovery and implementation of novel molecular and nano-technologies, cellular research now has advanced to assessing signal transduction pathways, gene editing, and gene therapies. The contribution of heritable animal models to human and animal health as related to hemostasis is reviewed and updated with the advent of gene editing, recombinant and gene therapies.

25 August 2025 in Veterinary Clinics of North America: Small Animal Practice
Verified
Journal Article
Closed access
W. Jean  DoddsW. Jean Dodds
W. Jean Dodds